Lantern Pharma Inc. Operating Expenses
Lantern Pharma Inc. (LTRN) reported Operating Expenses of $3.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Lantern Pharma Inc. operating expenses for the quarter ending 2026-06-30 was $3.51M, a 24.59% decline year-over-year.
- Lantern Pharma Inc. operating expenses for the quarter ending 2026-03-31 was $3.41M, a 28.67% decline year-over-year.
- Lantern Pharma Inc. operating expenses for the quarter ending 2025-12-31 was $4.20M, a 28.72% decline year-over-year.
- Lantern Pharma Inc. operating expenses for the quarter ending 2025-09-30 was $4.35M, a 16.02% decline year-over-year.
- Lantern Pharma Inc. operating expenses for fiscal 2025 was $17.98M, a 19.08% decline from fiscal 2024.
- Lantern Pharma Inc. operating expenses for fiscal 2024 was $22.22M, a 24.27% increase from fiscal 2023.
- Lantern Pharma Inc. operating expenses for fiscal 2023 was $17.88M, a 23.87% increase from fiscal 2022.
- Lantern Pharma Inc. operating expenses for fiscal 2022 was $14.43M, a 14.62% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.51M 10-Q · filed 2026-08-14 | $6.91M 10-Q · filed 2026-08-14 | $11.12M derived: sum of 3 quarters · filed 2026-08-14 | $15.47M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.41M 10-Q · filed 2026-05-15 | $7.61M derived: sum of 2 quarters · filed 2026-05-15 | $11.96M derived: sum of 3 quarters · filed 2026-05-15 | $16.61M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.55M derived: sum of 2 quarters · filed 2026-03-30 | $13.20M derived: sum of 3 quarters · filed 2026-08-14 | $17.98M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.35M 10-Q · filed 2025-11-12 | $9.00M derived: sum of 2 quarters · filed 2026-08-14 | $13.78M 10-Q · filed 2025-11-12 | $19.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $4.65M 10-Q · filed 2026-08-14 | $9.43M 10-Q · filed 2026-08-14 | $15.32M derived: sum of 3 quarters · filed 2026-08-14 | $20.50M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $4.77M 10-Q · filed 2026-05-15 | $10.67M derived: sum of 2 quarters · filed 2026-05-15 | $15.85M derived: sum of 3 quarters · filed 2026-05-15 | $21.26M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $11.08M derived: sum of 2 quarters · filed 2026-03-30 | $16.48M derived: sum of 3 quarters · filed 2026-03-30 | $22.22M 10-K · filed 2026-03-30 |
| 2024-09-30 | $5.18M 10-Q · filed 2025-11-12 | $10.59M derived: sum of 2 quarters · filed 2025-11-12 | $16.32M 10-Q · filed 2025-11-12 | $21.20M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $5.41M 10-Q · filed 2025-08-13 | $11.14M 10-Q · filed 2025-08-13 | $16.02M derived: sum of 3 quarters · filed 2025-08-13 | $19.54M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.73M 10-Q · filed 2025-05-15 | $10.61M derived: sum of 2 quarters · filed 2025-05-15 | $14.13M derived: sum of 3 quarters · filed 2025-05-15 | $19.32M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $8.40M derived: sum of 2 quarters · filed 2025-03-27 | $13.59M derived: sum of 3 quarters · filed 2025-03-27 | $17.88M 10-K · filed 2025-03-27 |
| 2023-09-30 | $3.52M 10-Q · filed 2024-11-07 | $8.71M derived: sum of 2 quarters · filed 2024-11-07 | $13.00M 10-Q · filed 2024-11-07 | $16.83M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.19M 10-Q · filed 2024-08-08 | $9.48M 10-Q · filed 2024-08-08 | $13.30M derived: sum of 3 quarters · filed 2024-08-08 | $15.45M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.29M 10-Q · filed 2024-05-09 | $8.11M derived: sum of 2 quarters · filed 2024-05-09 | $10.26M derived: sum of 3 quarters · filed 2024-05-09 | $14.65M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $5.97M derived: sum of 2 quarters · filed 2024-03-18 | $10.37M derived: sum of 3 quarters · filed 2024-03-18 | $14.43M 10-K · filed 2024-03-18 |
| 2022-09-30 | $2.15M 10-Q · filed 2023-11-08 | $6.54M derived: sum of 2 quarters · filed 2023-11-08 | $10.61M 10-Q · filed 2023-11-08 | $14.12M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $4.39M 10-Q · filed 2023-08-09 | $8.46M 10-Q · filed 2023-08-09 | $11.97M derived: sum of 3 quarters · filed 2023-08-09 | $16.12M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $4.07M 10-Q · filed 2023-05-09 | $7.58M derived: sum of 2 quarters · filed 2023-05-09 | $11.73M derived: sum of 3 quarters · filed 2023-05-09 | $14.21M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $7.66M derived: sum of 2 quarters · filed 2023-03-20 | $10.14M derived: sum of 3 quarters · filed 2023-03-20 | $12.59M 10-K · filed 2023-03-20 |
| 2021-09-30 | $4.15M 10-Q · filed 2022-11-07 | $6.63M derived: sum of 2 quarters · filed 2022-11-07 | $9.08M 10-Q · filed 2022-11-07 | $11.98M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $2.48M 10-Q · filed 2022-08-08 | $4.93M 10-Q · filed 2022-08-08 | $7.83M derived: sum of 3 quarters · filed 2022-08-08 | $9.53M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $2.45M 10-Q · filed 2022-05-03 | $5.35M derived: sum of 2 quarters · filed 2022-05-03 | $7.05M derived: sum of 3 quarters · filed 2022-05-03 | $7.88M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $4.60M derived: sum of 2 quarters · filed 2022-03-10 | $5.43M derived: sum of 3 quarters · filed 2022-03-10 | $5.91M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.70M 10-Q · filed 2021-11-01 | $2.53M derived: sum of 2 quarters · filed 2021-11-01 | $3.01M 10-Q · filed 2021-11-01 | $3.69M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $833.42K 10-Q · filed 2021-07-29 | $1.31M 10-Q · filed 2021-07-29 | $1.99M derived: sum of 3 quarters · filed 2021-07-29 | $2.66M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $477.28K 10-Q · filed 2021-05-03 | $1.15M derived: sum of 2 quarters · filed 2021-05-03 | $1.82M derived: sum of 3 quarters · filed 2021-05-03 | $2.45M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $675.17K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $1.34M derived: sum of 2 quarters · filed 2021-03-10 | $1.97M derived: sum of 3 quarters · filed 2021-03-10 | $2.43M 10-K · filed 2021-03-10 |
| 2019-09-30 | $669.65K 10-Q · filed 2020-10-29 | $1.30M derived: sum of 2 quarters · filed 2020-10-29 | $1.75M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $629.39K 10-Q · filed 2020-07-30 | $1.08M 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |